@__ice9

I do quantitative things. Sometimes I think about society and economics.

 Chicago, IL
Joined January 2017
  • Tweets65.4K
  • Following2K
  • Followers7.8K
3.5KMedia
paulgraham.com/say.html
11
17
3
111
Again, the most useful points for a broad audience: - get vaccine ASAP; prefer mRNA or Novavax; 2 doses far better than 1 - store RCT-validated early treatments: bromhexine-or-ambroxol + nitazoxanide-or-niclosamide, fluvoxamine, ivermectin - N100 masks xitter.cf/__ice9/status/13654419…
ice9@__ice926 Feb 2021
Remembered: badly needed to link the dual entry inhibition thread; people keep not recalling what it is. Basically-- One of: - bromhexine - ambroxol - maybe-camostat (but highest dose needed...) And: - Nitazoxanide - Niclosamide - RCT: HCQ (sry but yes) xitter.cf/__ice9/status/13525245…
21
46
25
203
more replies
If in doubt, *ask the patient*. People have a fundamental right to participate in their own health-- *they already do so 99% of the time anyway*. 'This might help with X; it's a bit less certain; may cause Y side effects; studies say usually well-tolerated; do you want to try?'
2
12
4
102
Informed consent is a thing. Most people facing a potentially crippling or lethal illness have a much greater risk tolerance against 'well maybe item 6 of 11 didn't do much to help here in retrospect' than you likely think. That already happens often in routine practice anyway!
4
8
2
97
Reuse of N95 and related masks, a review of 42 studies jamanetwork.com/journals/jam… Comparison of merits of 5 different methods for retaining filtration jamanetwork.com/journals/jam… @JAMA_current by @MSchumm90 and colleagues @UCLAHealth 😷
4
62
2
166
Current COVID-19 national vaccine coverage scoreboard-- nytimes.com/interactive/2021…
4
2
1
34
The prototype and story of a #LongCovid individual: young, healthy and mild illness thelancet.com/journals/lanre… @LancetRespirMed
8
125
22
313
If Marshall or Jenner ran their now famous experiments today, they would likely be written off as curiosities.
3
4
36
This truly is the time of the cicadas. Every strategy with merit deserves its own time in the sun. 🌥️🌤️☀️ 📈 Or moonlight, clandestine economy, filling gaps even at edges, choke points. 🌑🌒🌓🌔🌕🎴 Sometimes even spectacular. Fly.... ☄️ Glory to the forgetful. ⏳⌛
8
6
3
50
ice9 retweeted
ice9@__ice928 Feb 2021
The continued failure to trial or use ITPP in critical care is an indictment against the regulatory and productive institutions of our supposedly-advanced (increasingly just shorthand for 'gridlocked') economy. en.wikipedia.org/wiki/Myo-in… It makes blood transport oxygen better.
5
22
5
114
The continued failure to trial or use ITPP in critical care is an indictment against the regulatory and productive institutions of our supposedly-advanced (increasingly just shorthand for 'gridlocked') economy. en.wikipedia.org/wiki/Myo-in… It makes blood transport oxygen better.
5
22
5
114
more replies
@patrickc @balajis If you want a real impact in reducing ICU deaths, look into ITPP, while doing cyproheptadine and fluvoxamine. Yes I know I am terrible with DMs. Yes I know I am handicapped by pseudonymity. I will never use WhatsApp. Just do it. My issues are irrelevant.
4
11
2
63
By the way I wrote that wiki article too. No one else was doing it. Someone had to stand up.
5
6
71
ice9 retweeted
ice9@__ice926 Feb 2021
Remembered: badly needed to link the dual entry inhibition thread; people keep not recalling what it is. Basically-- One of: - bromhexine - ambroxol - maybe-camostat (but highest dose needed...) And: - Nitazoxanide - Niclosamide - RCT: HCQ (sry but yes) xitter.cf/__ice9/status/13525245…
ice9@__ice926 Feb 2021
Replying to @__ice9
I am... actually not kidding about the bitcoin thing. bc1qhe66mf32tkcn5z6qadjxqw2a7eqhzamgvcgv7z Things are not going especially well, and I can't easily doxx myself to collaborate irl. If you think it all has been worth something, feel free to send whatever you think is fair.
6
29
22
126
Efficacy is nowhere near Novavax or the mRNA options (Pfizer/Moderna). Much like Sinovac/Sinopharm(/CanSino), the tell for this is the headline numbers focusing solely on severe COVID-19 and ignoring mild/moderate cases.
The Associated Press
@AP27 Feb 2021
Replying to @AP
The FDA said J&J’s vaccine offers strong protection against what matters most: serious illness, hospitalizations and death. One dose was 85% protective against the most severe COVID-19 illness, in a massive study that spanned three continents. apne.ws/P28locC

J&J’s 1-dose shot cleared, giving US 3rd COVID-19 vaccine

WASHINGTON (AP) — The U.S. is getting a third vaccine to prevent COVID-19, as the Food and Drug Administration on Saturday cleared a Johnson & Johnson shot that works with just one dose instead of...

apnews.com
3
7
2
77
more replies
Many media outlets are reporting the 66% figure as though it were for mild cases. That interpretation is totally incorrect; the company plainly states that it is for *moderate* cases: jnj.com/johnson-johnson-anno… Definitions for moderate and severe broadly match prior literature:
2
3
32
Example: this article from ABC is blatantly inaccurate. abc11.com/johnson-and-jansen… 66% for J&J is for *moderate* cases, whereas 95% for mRNA is for *any case at all by RT-PCR*. It is absolutely incorrect to compare these figures, like comparing choking to hiccups.
1
1
30
Load more